What Is Glutathione?

Visao Geral da Pesquisa

Glutathione (GSH) is a ubiquitous endogenous tripeptide que serves como o(a) principal intracellular antioxidante and redox buffer in mammalian biology. Composed of L-glutamate, L-cysteine, and glycine, it foi isolado(a) pela primeira vez and named by Frederick Gowland Hopkins in 1921, though its correct tripeptide structure nao foi estabeleceu until 1935 by Harington and Mead. Present at millimolar concentrations (0.5–10 mM) in virtually every cell, GSH participates in a vast network of antioxidante defense, detoxification, signal transduction, and immune modulacao processes que are essencial para cellular survival.[3][12]

GSH is biosintetizado(a) em the cytosol via a tightly regulou, two-step ATP-dependent enzymatic process. First, glutamate-cysteine ligase (GCL) catalyzes the formation of γ-glutamylcysteine from glutamate and cysteine (a taxa-limiting step); then glutathione synthetase (GS) adds glycine para o(a) C-terminal to yield the final molecule. The availability of cysteine is o(a) principal rate-limiting factor in this synthesis. The liver serves como o(a) principal production organ e o(a) main source of plasma GSH for interorgan distribuicao.[12][20]

The therapeutic rationale for GSH research is grounded in its role como o(a) body's "master antioxidante." GSH directly neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS), serves como o(a) essencial cofactor for glutathione peroxidases (GPx), and conjugates with electrophilic toxins and heavy metals via glutathione S-transferases (GSTs) for excrecao (Phase II detoxification). The ratio of reduziu GSH to oxidized GSSG serves como um(a) fundamental index of cellular oxidative status; a decline in this ratio is a hallmark of estresse oxidativo, cellular dysfunction, and aging.[3][12]

Clinical research has estabeleceu que GSH depletion is implicated no(a) pathology of numerosos(as) conditions. In Parkinson's disease, GSH depletion no(a) substantia nigra precedes neurodegeneration, and intranasal GSH (600 mg/day) melhorou UPDRS scores in a Phase IIb trial (P = 0.0025).[11][5] In doenca hepatico(a)a, oral GSH (300 mg/day) reduziu significativamente alanine transaminase (ALT) in NAFLD subjects.[8] In dermatology, ambos(as) oral (250–500 mg/day) and topico(a) (2% GSSG) glutathione demonstrated significant reductions in melanin index, wrinkles, and improvements in skin elasticity in multiplos(as) randomizado controlled trials.[19][18][2] In diabetes tipo 2, 1000 mg/day oral GSH melhorou significativamente whole-body sensibilidade a insulina in obese males.[16] As a chemotherapy adjunct, IV glutathione (1.5 g/m²) reduziu cisplatin-associated neurotoxicity in gastric and ovarian cancer subjects sem compromising antineoplastic efficacy.[4][15]

A key challenge in GSH research is biodisponibilidade. Standard oral GSH has limited sistemico(a) availability due to degradacao by intestinal γ-glutamyl transpeptidase (GGT), and IV administration yields a plasma meia-vida of menos do que 3 minutes. Strategies to overcome this include liposomal encapsulation, sublingual delivery, intranasal administration (which aumenta brain GSH >200% within 45 minutes), e o(a) use of GSH precursors como N-acetylcysteine (NAC).[14][20][9]